CYP4F2 1347 G>A & GGCX 12970 C>G polymorphisms: Frequency in north indians & their effect on dosing of acenocoumarol oral anticoagulant

Indian Journal of Medical Research

Volumn 139, Issue APR, 2014, Pages 572-578

  Rathore, Saurabh Singh ^a   Agarwal, Surendra Kumar ^a   Pande, Shantanu ^a   Singh, Sushil Kumar ^b   Mittal, Tulika ^a   Mittal, Balraj ^a  

^a SANJAY GANDHI POSTGRADUATE INSTITUTE OF MEDICAL SCIENCES   (India)

^b KING GEORGE'S MEDICAL UNIVERSITY   (India)

Author keywords

Allele frequency; Anticoagulant; CYP2C9; GGCX; North indians; Pharmacogenetics; Polymorphism

Indexed keywords

ACENOCOUMAROL; CYTOCHROME; CYTOCHROME P450 4F2; GAMMA GLUTAMYL HYDROLASE; UNCLASSIFIED DRUG; ANTICOAGULANT AGENT; CYP4F2 PROTEIN, HUMAN; CYTOCHROME P450; GLUTAMYL CARBOXYLASE; LIGASE; PHARMACOLOGICAL BIOMARKER;

ADULT; ALLELE; ARTICLE; CONTROLLED STUDY; CYP4F2 GENE; DNA POLYMORPHISM; DRUG RESPONSE; FEMALE; GAMMA GLUTAMYL CARBOXYLASE GENE; GENE; GENE FREQUENCY; GENETIC ASSOCIATION; GENOTYPE; GENOTYPING TECHNIQUE; HEART VALVE REPLACEMENT; HUMAN; MAJOR CLINICAL STUDY; MALE; PHARMACOGENETICS; POLYMERASE CHAIN REACTION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; GENETICS; INDIA; PROCEDURES; SINGLE NUCLEOTIDE POLYMORPHISM; STATISTICAL MODEL;

ACENOCOUMAROL; ANTICOAGULANTS; BIOMARKERS, PHARMACOLOGICAL; CARBON-CARBON LIGASES; CYTOCHROME P-450 ENZYME SYSTEM; GENE FREQUENCY; HEART VALVE PROSTHESIS IMPLANTATION; HUMANS; INDIA; LOGISTIC MODELS; PHARMACOGENETICS; POLYMERASE CHAIN REACTION; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 84902143892     PISSN: 09715916     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Wadelius M, Pirmohamed M. Pharmacogenetics of warfarin: current status and future challenges. Pharmacogenomics J 2007; 7: 99-111.
2. Limdi NA, Veenstra DL. Warfarin pharmacogenetics. Pharmacotherapy 2008; 28: 1084-97.
3. Schelleman H, Limdi NA, Kimmel SE. Ethnic differences in warfarin maintenance dose requirement and its relationship with genetics. Pharmacogenomics 2008; 9: 1331-46.
4. Takeuchi F, McGinnis R, Bourgeois S, Barnes C, Eriksson N, Soranzo N, et al. A genome-wide association study confirms VKORC1, CYP2C9, and CYP4F2 as principal genetic determinants of warfarin dose. PLoS Genet 2009; 5: e1000433.
5. Teichert M, van Schaik RH, Hofman A, Uitterlinden AG, de Smet PA, Stricker BH, et al. Genotypes associated with reduced activity of VKORC1 and CYP2C9 and their modification of acenocoumarol anticoagulation during the initial treatment period. Clin Pharmacol Ther 2009; 85: 379-86.
6. Cha PC, Mushiroda T, Takahashi A, Kubo M, Minami S, Kamatani N, et al. Genome-wide association study identifies genetic determinants of warfarin responsiveness for Japanese. Hum Mol Genet 2010; 19: 4735-44.
7. Caldwell MD, Awad T, Johnson JA, Gage BF, Falkowski M, Gardina P, et al. CYP4F2 genetic variant alters required warfarin dose. Blood 2008; 111: 4106-12.
8. Rieder MJ, ReinerAP, RettieAE. Gamma-glutamyl carboxylase (GGCX) tagSNPs have limited utility for predicting warfarin maintenance dose. J Thromb Haemost 2007; 5: 2227-34.
9. Barrett JC, Fry B, Maller J, Daly MJ. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 2005; 21: 263-5.
10. Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 1988; 16: 1215.
11. Deng S, Zhu G, Liu F, Zhang H, Qin X, Li L, et al. CYP4F2 gene V433M polymorphism is associated with ischemic stroke in the male Northern Chinese Han population. Prog Neuropsychopharmacol Biol Psychiatry 2010; 34: 664-8.
12. Zeng WT, Zheng QS, Huang M, Cen HJ, Lai Y, Chen WY, et al. Genetic polymorphisms of VKORC1, CYP2C9, CYP4F2 in Bai, Tibetan Chinese. Pharmazie 2012; 67: 69-73.
13. Vargens DD, Damasceno A, Petzl-Erler ML, Suarez-Kurtz G. Combined CYP2C9, VKORC1 and CYP4F2 frequencies among Amerindians, Mozambicans and Brazilians. Pharmacogenomics 2011; 12: 769-72.
14. Hirsh J, Dalen J, Anderson DR, Poller L, Bussey H, Ansell J, et al. Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest 2001; 119 (Suppl 1): 8S-21S.
15. Gage BF, Eby C, Johnson JA, Deych E, Rieder MJ, Ridker PM, et al. Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin. Clin Pharmacol Ther 2008; 84: 326-31.
16. Wu AH, Wang P, Smith A, Haller C, Drake K, Linder M, et al. Dosing algorithm for warfarin using CYP2C9 and VKORC1 genotyping from a multi-ethnic population: comparison with other equations. Pharmacogenomics 2008; 9: 169-78.
17. International Warfarin Pharmacogenetics Consartium, Klein TE, Altman RB, Eriksson N, Gage BF, Kimmel SE, Lee MT, et al. Estimation of the warfarin dose with clinical and pharmacogenetic data. N Engl J Med 2009; 360: 753-64.
18. Cooper GM, Johnson JA, Langaee TY, Feng H, Stanaway IB, Schwarz UI, et al. A genome-wide scan for common genetic variant with a large influence on warfarin maintenance dose. Blood 2008; 112: 1022-7.
19. Rathore SS, Agarwal SK, Pande S, Singh SK, Mittal T, Mittal B. Therapeutic dosing of acenocoumarol: proposal of a population specific pharmacogenetic dosing algorithm and its validation in north indians. PLoS One 2012; 7: e37844.
20. Liang R, Li L, Li C, Gao Y, Liu W, Hu D, et al. Impact of CYP2C9*3, VKORC1-1639, CYP4F2rs2108622 genetic polymorphism and clinical factors on warfarin maintenance dose in Han-Chinese patients. J Thromb Thrombolysis 2012; 34: 120-5.
21. Wells PS, Majeed H, Kassem S, Langlois N, Gin B, Clermont J, et al. A regression model to predict warfarin dose from clinical variables and polymorphisms in CYP2C9, CYP4F2, and VKORC1: Derivation in a sample with predominantly a history of venous thromboembolism. Thromb Res 2010; 125: e259-64.